Developer docs
API playgroundTry for free, no card

Search company profiles

Pliant Therapeutics

Full company profile

uuid0002do5

Namestring
Pliant Therapeutics
Legal namestring
Pliant Therapeutics, Inc.
Websiteurl
pliantrx.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Pliant Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing integrin-based therapeutics for serious diseases with limited treatment options. The company's scientific foundation is a proprietary integrin drug discovery and delivery platform comprising a library of over 15,000 integrin binding molecules, comprehensive binding and internalization screening assays, and an industry-leading live human tissue program. Its lead clinical candidate is PLN-101095, an oral dual αvβ8/αvβ1 integrin inhibitor designed to block TGF-β activation in the tumor microenvironment and resensitize tumors to immune checkpoint inhibitors; this asset is being evaluated in the FORTIFY Phase 1b trial in combination with pembrolizumab for patients with ICI-refractory advanced or metastatic solid tumors, including non-small cell lung cancer, clear cell renal cell carcinoma, and high tumor mutational burden tumors. Prior lead asset bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis and primary sclerosing cholangitis was discontinued following a Phase 3 failure, prompting a strategic pivot to oncology.

Pliant generates no product revenue and operates a clinical-development GTM motion centered on advancing candidates through regulatory milestones, presenting at medical conferences (ASCO, AACR, SITC, ERS, ATS), and engaging institutional investors and healthcare-focused investment banks (RBC Capital Markets, Oppenheimer, Piper Sandler). Patient recruitment for the FORTIFY trial is conducted through clinicaltrials.gov and direct site enrollment. Capital is raised via public equity offerings; the company has completed upsized public offerings of $200M (July 2022) and $250M (January 2023), and in March 2026 launched a $50M at-the-market equity program with Leerink Partners. As of Q4 2025, the company held $192.4M in cash and short-term investments, expected to fund operations into the second half of 2028, and reported a quarterly net loss of $23.6M with R&D expenses of $15.6M (down from $38.8M year-over-year following the IPF program wind-down). The company is listed on NASDAQ under ticker PLRX with approximately 97.3% institutional ownership, though shares trade near 52-week lows with a market capitalization of approximately $70-80M.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
integrin-based therapeutics, clinical-stage biopharmaceutical, fibrotic disease treatment, oncology drug development, tumor microenvironment therapy
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage biopharmaceutical — integrin-based therapeutics
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biopharmaceutical company, Pliant is pre-revenue and does not currently have approved products. The company is developing PLN-101095 for solid tumors and bexotegrast (PLN-74809) for fibrotic diseases. Revenue will be generated upon regulatory approval and commercialization of drug candidates.

biospace.com
2At-the-Market (ATM) Equity Program
TypeSubscription Recurring
Description

Company launched a $50 million at-the-market equity program enabling sale of common stock through Leerink Partners as sales agent. This provides flexible capital access without traditional underwritten offering.

tradingview.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1FORTIFY
Description

Phase 1b clinical study evaluating PLN-101095 in combination with pembrolizumab for the treatment of solid tumors.

pliantrx.com
+1 more record
Core offering1 text field

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics, with its lead candidate PLN-101095—an oral dual αvβ8/αvβ1 integrin inhibitor—currently in the FORTIFY Phase 1a/1b trial in combination with pembrolizumab for patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Discovery and development are powered by a proprietary Integrin Drug Delivery Platform built on over 15,000 integrin binding molecules, screening assays, and a live human tissue program. Prior fibrosis programs (bexotegrast/PLN-74809) were discontinued following Phase 3 failure.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 89% average maximum tumor reduction from baseline in responders
+3 more records
Product overview1 text field

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics. The company's lead product is PLN-101095, an oral dual αvβ8/αvβ1 integrin inhibitor currently in Phase 1a/1b clinical trials for solid tumors. This is being evaluated in the FORTIFY study in combination with pembrolizumab for patients whose cancers have become resistant to immune checkpoint inhibitors. The company leverages its proprietary Integrin Drug Delivery Platform—which includes over 15,000 integrin binding molecules and screening assay systems—to discover and develop additional targeted therapies. Prior programs included bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, but these were discontinued following Phase 3 trial failure.

Product and service3 records
1PLN-101095
CategoryInvestigational oncology drug candidate (integrin inhibitor)
Description

An oral dual αvβ8/αvβ1 integrin inhibitor being developed for the treatment of solid tumors. It is designed to overcome immune checkpoint inhibitor (ICI) resistance by blocking TGF-β activation in the tumor microenvironment, potentially resensitizing tumors refractory to checkpoint inhibitors such as pembrolizumab.

2Integrin Drug Delivery Platform
CategoryProprietary drug discovery and delivery platform
Description

A proprietary drug discovery and delivery platform comprising a library of over 15,000 integrin binding molecules, comprehensive screening assays for binding, integrin confirmation, and ligand-induced internalization, and a live human tissue program. The platform enables development of integrin-targeted therapies and supports tissue-specific drug delivery to muscle and adipose tissue.

3FORTIFY Study
CategoryClinical trial / investigational study
Description

A Phase 1b clinical study evaluating PLN-101095 in combination with pembrolizumab (KEYTRUDA) for adults with advanced or metastatic solid tumors that have become refractory to immune checkpoint inhibitors. Enrolling patients across NSCLC, clear cell renal cell carcinoma, and high tumor mutational burden tumor cohorts.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pliant is conducting the FORTIFY Phase 1b trial evaluating PLN-101095 in combination with pembrolizumab (KEYTRUDA), Merck's PD-1 checkpoint inhibitor, for patients with ICI-refractory advanced or metastatic solid tumors. Pembrolizumab is administered every 3 weeks during the combination treatment period.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Morphic Holding
TypeDirect peer
Description

Clinical-stage biotech developing oral integrin inhibitors for fibrosis, immunology, and metabolic disease. Directly comparable as a small-molecule integrin-targeted therapeutics company with a similar scientific thesis, though acquired by Eli Lilly in 2024, illustrating both the strategic value of the integrin space and the difficulty of independent commercialization.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing combinations to overcome or extend checkpoint inhibitor response, including adenosine and TIGIT pathways. Comparable to Pliant in targeting ICI resistance mechanisms and running checkpoint-inhibitor combination trials in similar tumor types.

TypeDirect peer
Description

Clinical-stage biotech developing therapeutics that target TGF-β superfamily activation, including latent TGF-β. Comparable because Pliant's PLN-101095 works in the same TGF-β activation pathway via integrin blockade, and Scholar Rock's fibrosis and oncology programs parallel Pliant's historical and current pipeline focus.

TypeDirect peer
Description

Clinical-stage immuno-oncology company using computational target discovery to identify novel targets that modulate the tumor immune microenvironment. Comparable in clinical-stage status, oncology focus, and the strategy of finding first-in-class targets to combine with checkpoint inhibitors.

TypeDirect peer
Description

Clinical-stage oncology company developing INDUKINE prodrugs designed to be activated in the tumor microenvironment to overcome the limitations of systemic immune activation. Comparable as a small, clinical-stage oncology platform player targeting the same problem of potentiating checkpoint inhibitor response.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing antibody-drug conjugates and immunotherapies, including programs intended to combine with or resensitize tumors to checkpoint inhibitors. Comparable as a small-cap clinical oncology company pursuing novel immuno-oncology combinations.

TypeBroad incumbent
Description

Commercial-stage biopharma with late-stage and marketed fibrosis assets, historically including IPF programs. Comparable given Pliant's prior IPF franchise with bexotegrast and its continuing PSC work, providing a read on competitive dynamics and commercial benchmarks in fibrotic disease.

TypeDirect peer
Description

Clinical-stage immuno-oncology company developing T-cell engagers designed to overcome resistance and improve responses in solid tumors. Comparable as a clinical-stage peer combining novel immune mechanisms with checkpoint inhibition; acquired by Merck in 2024, signaling big-pharma appetite for the same clinical-stage oncology assets Pliant is developing.

TypeEmerging player
Description

Clinical-stage oncology company using a proprietary antibody discovery and engineering platform to generate conditionally active antibodies. Comparable as a platform-driven clinical-stage oncology peer with similar headcount and stage, focused on novel mechanisms to improve immuno-oncology outcomes.

TypeEmerging player
Description

Clinical-stage biotech developing next-generation ADCs using an integrator/integrin-targeting linker concept. Comparable as an emerging player in the integrin-targeted oncology space, intersecting with Pliant's integrin biology expertise and platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pliant Therapeutics

Clinical-stage biopharmaceutical — integrin-based therapeuticspliantrx.com

What Pliant Therapeutics does

Pliant Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, developing integrin-based therapeutics for serious diseases with limited treatment options. The company's scientific foundation is a proprietary integrin drug discovery and delivery platform comprising a library of over 15,000 integrin binding molecules, comprehensive binding and internalization screening assays, and an industry-leading live human tissue program. Its lead clinical candidate is PLN-101095, an oral dual αvβ8/αvβ1 integrin inhibitor designed to block TGF-β activation in the tumor microenvironment and resensitize tumors to immune checkpoint inhibitors; this asset is being evaluated in the FORTIFY Phase 1b trial in combination with pembrolizumab for patients with ICI-refractory advanced or metastatic solid tumors, including non-small cell lung cancer, clear cell renal cell carcinoma, and high tumor mutational burden tumors. Prior lead asset bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis and primary sclerosing cholangitis was discontinued following a Phase 3 failure, prompting a strategic pivot to oncology.

Pliant generates no product revenue and operates a clinical-development GTM motion centered on advancing candidates through regulatory milestones, presenting at medical conferences (ASCO, AACR, SITC, ERS, ATS), and engaging institutional investors and healthcare-focused investment banks (RBC Capital Markets, Oppenheimer, Piper Sandler). Patient recruitment for the FORTIFY trial is conducted through clinicaltrials.gov and direct site enrollment. Capital is raised via public equity offerings; the company has completed upsized public offerings of $200M (July 2022) and $250M (January 2023), and in March 2026 launched a $50M at-the-market equity program with Leerink Partners. As of Q4 2025, the company held $192.4M in cash and short-term investments, expected to fund operations into the second half of 2028, and reported a quarterly net loss of $23.6M with R&D expenses of $15.6M (down from $38.8M year-over-year following the IPF program wind-down). The company is listed on NASDAQ under ticker PLRX with approximately 97.3% institutional ownership, though shares trade near 52-week lows with a market capitalization of approximately $70-80M.

Pliant Therapeutics firmographics

Firmographics
Name
Pliant Therapeutics
Legal name
Pliant Therapeutics, Inc.
Website
https://pliantrx.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Pliant Therapeutics industry classification

Industry
Product category
Clinical-stage biopharmaceutical — integrin-based therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Integrin-based therapeutics
  • Clinical-stage biopharmaceutical
  • Fibrotic disease treatment
  • Oncology drug development
  • Tumor microenvironment therapy

Where Pliant Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pliant Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: As a clinical-stage biopharmaceutical company, Pliant is pre-revenue and does not currently have approved products. The company is developing PLN-101095 for solid tumors and bexotegrast (PLN-74809) for fibrotic diseases. Revenue will be generated upon regulatory approval and commercialization of drug candidates.
  2. At-the-Market (ATM) Equity Program: Company launched a $50 million at-the-market equity program enabling sale of common stock through Leerink Partners as sales agent. This provides flexible capital access without traditional underwritten offering.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Pliant Therapeutics product offering

Product offering

Core offering

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics, with its lead candidate PLN-101095—an oral dual αvβ8/αvβ1 integrin inhibitor—currently in the FORTIFY Phase 1a/1b trial in combination with pembrolizumab for patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Discovery and development are powered by a proprietary Integrin Drug Delivery Platform built on over 15,000 integrin binding molecules, screening assays, and a live human tissue program. Prior fibrosis programs (bexotegrast/PLN-74809) were discontinued following Phase 3 failure.

Product overview

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics. The company's lead product is PLN-101095, an oral dual αvβ8/αvβ1 integrin inhibitor currently in Phase 1a/1b clinical trials for solid tumors. This is being evaluated in the FORTIFY study in combination with pembrolizumab for patients whose cancers have become resistant to immune checkpoint inhibitors. The company leverages its proprietary Integrin Drug Delivery Platform—which includes over 15,000 integrin binding molecules and screening assay systems—to discover and develop additional targeted therapies. Prior programs included bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, but these were discontinued following Phase 3 trial failure.

Differentiator

Problem solved

Functional benefit

Brands

  • FORTIFY: Phase 1b clinical study evaluating PLN-101095 in combination with pembrolizumab for the treatment of solid tumors.
  • Integrin Drug Delivery Platform

Products and services

  • PLN-101095 An oral dual αvβ8/αvβ1 integrin inhibitor being developed for the treatment of solid tumors. It is designed to overcome immune checkpoint inhibitor (ICI) resistance by blocking TGF-β activation in the tumor microenvironment, potentially resensitizing tumors refractory to checkpoint inhibitors such as pembrolizumab.
  • Integrin Drug Delivery Platform A proprietary drug discovery and delivery platform comprising a library of over 15,000 integrin binding molecules, comprehensive screening assays for binding, integrin confirmation, and ligand-induced internalization, and a live human tissue program. The platform enables development of integrin-targeted therapies and supports tissue-specific drug delivery to muscle and adipose tissue.
  • FORTIFY Study A Phase 1b clinical study evaluating PLN-101095 in combination with pembrolizumab (KEYTRUDA) for adults with advanced or metastatic solid tumors that have become refractory to immune checkpoint inhibitors. Enrolling patients across NSCLC, clear cell renal cell carcinoma, and high tumor mutational burden tumor cohorts.

Quantifiable outcome

  • 89% average maximum tumor reduction from baseline in responders
  • +3 more outcomes

Companies that use Pliant Therapeutics

Customer profile

Segments3 records

Ideal customer profiles2 records

Pliant Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Pliant Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Merck Sharp & Dohme LLC (MSD)coreStrategic or Co-development PartnerPliant is conducting the FORTIFY Phase 1b trial evaluating PLN-101095 in combination with pembrolizumab (KEYTRUDA), Merck's PD-1 checkpoint inhibitor, for patients with ICI-refractory advanced or metastatic solid tumors. Pembrolizumab is administered every 3 weeks during the combination treatment period.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Pliant Therapeutics competitors and assessment

Company assessment

Direct peers

  • Morphic Holding: Clinical-stage biotech developing oral integrin inhibitors for fibrosis, immunology, and metabolic disease. Directly comparable as a small-molecule integrin-targeted therapeutics company with a similar scientific thesis, though acquired by Eli Lilly in 2024, illustrating both the strategic value of the integrin space and the difficulty of independent commercialization.
  • Arcus Biosciences: Clinical-stage immuno-oncology company developing combinations to overcome or extend checkpoint inhibitor response, including adenosine and TIGIT pathways. Comparable to Pliant in targeting ICI resistance mechanisms and running checkpoint-inhibitor combination trials in similar tumor types.
  • Scholar Rock: Clinical-stage biotech developing therapeutics that target TGF-β superfamily activation, including latent TGF-β. Comparable because Pliant's PLN-101095 works in the same TGF-β activation pathway via integrin blockade, and Scholar Rock's fibrosis and oncology programs parallel Pliant's historical and current pipeline focus.
  • Compugen: Clinical-stage immuno-oncology company using computational target discovery to identify novel targets that modulate the tumor immune microenvironment. Comparable in clinical-stage status, oncology focus, and the strategy of finding first-in-class targets to combine with checkpoint inhibitors.
  • Werewolf Therapeutics: Clinical-stage oncology company developing INDUKINE prodrugs designed to be activated in the tumor microenvironment to overcome the limitations of systemic immune activation. Comparable as a small, clinical-stage oncology platform player targeting the same problem of potentiating checkpoint inhibitor response.
  • Pyxis Oncology: Clinical-stage immuno-oncology company developing antibody-drug conjugates and immunotherapies, including programs intended to combine with or resensitize tumors to checkpoint inhibitors. Comparable as a small-cap clinical oncology company pursuing novel immuno-oncology combinations.
  • Harpoon Therapeutics: Clinical-stage immuno-oncology company developing T-cell engagers designed to overcome resistance and improve responses in solid tumors. Comparable as a clinical-stage peer combining novel immune mechanisms with checkpoint inhibition; acquired by Merck in 2024, signaling big-pharma appetite for the same clinical-stage oncology assets Pliant is developing.

Broad incumbents

  • FibroGen: Commercial-stage biopharma with late-stage and marketed fibrosis assets, historically including IPF programs. Comparable given Pliant's prior IPF franchise with bexotegrast and its continuing PSC work, providing a read on competitive dynamics and commercial benchmarks in fibrotic disease.

Emerging players

  • Adagene: Clinical-stage oncology company using a proprietary antibody discovery and engineering platform to generate conditionally active antibodies. Comparable as a platform-driven clinical-stage oncology peer with similar headcount and stage, focused on novel mechanisms to improve immuno-oncology outcomes.
  • Adcendo: Clinical-stage biotech developing next-generation ADCs using an integrator/integrin-targeting linker concept. Comparable as an emerging player in the integrin-targeted oncology space, intersecting with Pliant's integrin biology expertise and platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Pliant Therapeutics social profiles

Digital presence

Pliant Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pliant Therapeutics leadership team

Management profile

Number of profiles

Profiles15 records

Pliant Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pliant Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pliant Therapeutics

What does Pliant Therapeutics do?

Pliant Therapeutics is a clinical-stage biopharmaceutical company developing integrin-based therapeutics, with its lead candidate PLN-101095—an oral dual αvβ8/αvβ1 integrin inhibitor—currently in the FORTIFY Phase 1a/1b trial in combination with pembrolizumab for patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Discovery and development are powered by a proprietary Integrin Drug Delivery Platform built on over 15,000 integrin binding molecules, screening assays, and a live human tissue program. Prior fibrosis programs (bexotegrast/PLN-74809) were discontinued following Phase 3 failure.

Is Pliant Therapeutics a public or private company?

Pliant Therapeutics is a public company. It is classified as public and is currently operating.

When was Pliant Therapeutics founded?

Pliant Therapeutics was founded in 2018. It employs 51 to 100 people.

Where is Pliant Therapeutics based?

Pliant Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Pliant Therapeutics make money?

Two revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are at-the-Market (ATM) Equity Program.

Who are Pliant Therapeutics's main competitors?

Direct peers on record are Morphic Holding, Arcus Biosciences, Scholar Rock, Compugen, Werewolf Therapeutics, Pyxis Oncology and Harpoon Therapeutics. FibroGen is listed as a broad incumbent. Emerging players are Adagene and Adcendo.

Does Pliant Therapeutics have an API?

No public API is recorded for Pliant Therapeutics.

What industry is Pliant Therapeutics in?

Pliant Therapeutics's product category is Clinical-stage biopharmaceutical — integrin-based therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsPliant Therapeutics (NASDAQ:PLRX) versus Arbutus Biopharma (NASDAQ:ABUS) Head-To-Head ComparisonA head-to-head comparison of Arbutus Biopharma and Pliant Therapeutics evaluates their ratings, risk, ownership, and profitability. Arbutus beats Pliant on 9 of 12 factors, with higher revenue and earnings, while Pliant shows higher analyst upside. Pliant's beta is 1.36 versus Arbutus's 0.84.Business & FinancialPliant Therapeutics Announces Presentation Of PLN-101095 Preclinical And Clinical Data At The 2026 Annual Meeting Of The Society For Immunotherapy Of CancerPliant Therapeutics presented preclinical and clinical data on PLN-101095 at the 2026 Society for Immunotherapy of Cancer meeting, showing that blocking integrins αvβ8 and αvβ1 with anti-PD-1 improved anti-tumor activity. The data support an ongoing Phase 1 trial of PLN-101095 with pembrolizumab in ICI-refractory solid tumors.Stock TitanPliant Therapeutics to Present PLN-101095 at SITC 2026Pliant Therapeutics announced two poster presentations of its integrin inhibitor PLN-101095 at the SITC 2026 meeting in Phoenix, November 4-8. The presentations cover selective targeting of integrins and plasma biomarkers predicting sensitization to immune checkpoint inhibition. The drug is being evaluated in the FORTIFY Phase 1a/1b trial with pembrolizumab for ICI-refractory solid tumors.MarketBeatPliant Therapeutics (PLRX) Set to Release Quarterly Earnings on ThursdayPliant Therapeutics is set to release Q3 2026 earnings on Thursday, November 5th, with analysts expecting a loss of $0.37 per share. The company previously missed estimates with a $0.36 loss, and analysts project a $1.42 loss for the current fiscal year. The stock opened at $0.89, with a consensus 'Hold' rating and a $3.00 target price.Business & FinancialPliant Therapeutics Announces Presentations At The 2026 Annual Meeting Of The Society For Immunotherapy Of CancerPliant Therapeutics announced two poster presentations at the 2026 Annual Meeting of the Society for Immunotherapy of Cancer, including results from a collaboration with the National Cancer Institute. The company's lead program, PLN-101095, is being evaluated in the FORTIFY Phase 1a/1b trial with pembrolizumab for ICI-refractory solid tumors.The future of tradingPliant Therapeutics to Present Phase 1b Cancer Trial at ESMO 2026Pliant Therapeutics will present its FORTIFY Phase 1b cancer trial at ESMO in Madrid on October 23, 2026. The trial enrolls patients with advanced solid tumors resistant to immune checkpoint inhibitors to evaluate PLN-101095 combined with pembrolizumab across three cohorts. The study assesses safety, tolerability, and preliminary antitumor activity.Stock TitanPliant to present PLN-101095 at ESMO Congress 2026Pliant Therapeutics announced a poster presentation at ESMO Congress 2026 on October 23, 2026, covering its FORTIFY trial of PLN-101095 with pembrolizumab in ICI-refractory solid tumors. The Phase 1b trial enrolls patients with NSCLC, high tumor mutational burden, or clear cell renal cell carcinoma, with dosing and combination therapy details provided.Markets DailyAbCellera Biologics (NASDAQ:ABCL) & Pliant Therapeutics (NASDAQ:PLRX) Critical AnalysisA comparison of Pliant Therapeutics and AbCellera Biologics evaluates profitability, institutional ownership, and analyst ratings. AbCellera Biologics beats Pliant on 11 of 15 factors, including higher revenue and a lower price-to-earnings ratio, though Pliant has higher institutional ownership and a higher potential upside.American Banking and Market NewsPliant Therapeutics, Inc. (NASDAQ:PLRX) Stock Rated “Reduce” by Wall Street BrokeragesWall Street brokerages rate Pliant Therapeutics stock as "Reduce" on average, with two sell ratings, one hold, and one buy. The average 1-year price target is $3.00, and the stock opened at $1.03. Institutional investors own 97.30% of the company's stock.MarketBeatPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Reduce" from AnalystsPliant Therapeutics received a consensus 'Reduce' rating from four analysts, with an average 1-year target price of $3.00. The company reported a Q2 EPS of -$0.36, missing the -$0.34 consensus estimate. Institutional investors hold 97.30% of the stock.